- Differences in the characteristics between patients receiving the 2 JAK inhibitors.
| Characteristics | Baricitinib | Upadacitinib |
|---|---|---|
| Mean age (range) years | 62 (30-82) | 57 (30-92) |
| DAS 28 CRP remission (total) | 41.0% | 19.0% |
| DAS 28 CRP remission (current) | 88.0% | 44.0% |
| Boolean response % (total) | 41.0% | 9.0% |
| Boolean response % (current) | 88.0% | 22.0% |
| Mean (range) time before stop (months) | 10.1 (3-24) | 4.6 (2-9) |
| Mean (range) time on drug | 21 (16-32) | 10.1 (4-20) |
| Biological-DMARDs naive | 82.0% | 46.0% |
| Biological-DMARDs failure | 18.0% | 54.0% |
| Age >50 | 88.0% | 68.0% |
| % of ≥2 CV risk in >50 | 29.0% | 9.0% |